Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Gynecology

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 55 articles: HTML format

Single Articles

April 2024
1. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
   Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913.
   Eur J Cancer. 2024 Apr 2:114017. doi: 10.1016/j.ejca.2024.114017.
   PubMed    
   
   
   March 2024
2. TUNINETTI V, Virano E, Salutari V, Ricotti A, et al
   Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
   Eur J Cancer. 2024;203:114039.
   PubMed     Abstract available
   
   
   
3. BOIDOT R, Blum MGB, Wissler MP, Gottin C, et al
   Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
   Eur J Cancer. 2024;202:113978.
   PubMed     Abstract available
   
   
   February 2024
4. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
   Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer.
   Eur J Cancer. 2024;201:113913.
   PubMed     Abstract available
   
   
   
5. TANAKA LF, Schoffer O, Schriefer D, Schauberger G, et al
   An audit of 1632 routinely collected cervical cancer screening smears from 398 women in Germany: Results from the TeQaZ Study.
   Eur J Cancer. 2024;201:113915.
   PubMed     Abstract available
   
   
   
6. LINDEMANN K, Kildal W, Kleppe A, Tobin KAR, et al
   Impact of molecular profile on prognosis and relapse pattern in low and intermediate risk endometrial cancer.
   Eur J Cancer. 2024;200:113584.
   PubMed     Abstract available
   
   
   January 2024
7. MATSUO K, Chen L, Neuman MK, Klar M, et al
   Low-grade endometrioid endometrial cancer with adnexal only metastasis: Evaluation of de-escalation of adjuvant therapy.
   Eur J Cancer. 2024;200:113533.
   PubMed     Abstract available
   
   
   
8. YANG Z, Zhang Y, Zhuo L, Sun K, et al
   Prediction of prognosis and treatment response in ovarian cancer patients from histopathology images using graph deep learning: a multicenter retrospective study.
   Eur J Cancer. 2024;199:113532.
   PubMed     Abstract available
   
   
   November 2023
9. NERO C, Bizzarri N, Di Berardino S, Sillano F, et al
   Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY).
   Eur J Cancer. 2023;196:113435.
   PubMed     Abstract available
   
   
   October 2023
10. SAVOYE I, Silversmit G, Bourgeois J, De Gendt C, et al
    Association between hospital volume and outcomes in invasive ovarian cancer in Belgium: A population-based study.
    Eur J Cancer. 2023;195:113402.
    PubMed     Abstract available
    
    
    
11. BIZZARRI N, Imterat M, Fruscio R, Giannarelli D, et al
    Lymph node staging in grade 1-2 endometrioid ovarian carcinoma apparently confined to the ovary: Is it worth?
    Eur J Cancer. 2023;195:113398.
    PubMed     Abstract available
    
    
    
12. LEARY A, Oaknin A, Trigo JM, Moreno V, et al
    Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
    Eur J Cancer. 2023;192:113259.
    PubMed     Abstract available
    
    
    September 2023
13. VERGOTE I, Matias-Guiu X
    New FIGO 2023 endometrial cancer staging validation. Welcome to the first molecular classifiers and new pathological variables!
    Eur J Cancer. 2023 Sep 27:113318. doi: 10.1016/j.ejca.2023.113318.
    PubMed    
    
    
    
14. WOJTYLA C, Bertuccio P, Giermaziak W, Santucci C, et al
    European trends in ovarian cancer mortality, 1990-2020 and predictions to 2025.
    Eur J Cancer. 2023;194:113350.
    PubMed     Abstract available
    
    
    
15. MATSUO K, Klar M, Song BB, Roman LD, et al
    Validation of the 2023 FIGO staging schema for advanced endometrial cancer.
    Eur J Cancer. 2023 Sep 21:113316. doi: 10.1016/j.ejca.2023.113316.
    PubMed    
    
    
    
16. PETRELLI F, Cavallone M, Dottorini L
    10 years or less of extended adjuvant endocrine therapy for postmenopausal breast cancer patients: A systematic review and network meta-analysis.
    Eur J Cancer. 2023;193:113322.
    PubMed     Abstract available
    
    
    
17. SCHWAMEIS R, Fanfani F, Ebner C, Zimmermann N, et al
    Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
    Eur J Cancer. 2023 Sep 1:113317. doi: 10.1016/j.ejca.2023.113317.
    PubMed     Abstract available
    
    
    August 2023
18. DING S, Li H
    Re: A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023 Aug 1:112978. doi: 10.1016/j.ejca.2023.112978.
    PubMed    
    
    
    July 2023
19. HOWROYD LR, Cornell I, Benson C, Napolitano A, et al
    Pseudoprogression in patients with uterine leiomyosarcoma treated with first-line single-agent doxorubicin.
    Eur J Cancer. 2023;192:113261.
    PubMed     Abstract available
    
    
    
20. CORBAUX P, You B, Glasspool RM, Yanaihara N, et al
    Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis.
    Eur J Cancer. 2023;191:112966.
    PubMed     Abstract available
    
    
    June 2023
21. VALENZA C, Trapani D, Gandini S, Sposetti C, et al
    Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments.
    Eur J Cancer. 2023;190:112944.
    PubMed     Abstract available
    
    
    May 2023
22. GONZALEZ-MARTIN A, Pothuri B, Vergote I, Graybill W, et al
    Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer.
    Eur J Cancer. 2023 May 3:S0959-8049(23)00225-3. doi: 10.1016/j.ejca.2023.
    PubMed     Abstract available
    
    
    April 2023
23. LOVERIX L, Vergote I, Busschaert P, Vanderstichele A, et al
    PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2023;188:131-139.
    PubMed     Abstract available
    
    
    
24. PETERS ITA, Marchetti C, De Palma A, Giannarelli D, et al
    Cytoreductive surgery for advanced epithelial ovarian cancer in the poly(ADP-ribose) polymerase inhibitors era-Is it time for a new paradigm shift? A systematic review and meta-analysis.
    Eur J Cancer. 2023;187:77-86.
    PubMed     Abstract available
    
    
    March 2023
25. LORUSSO D, Colombo N, Herraez AC, Santin AD, et al
    Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
    Eur J Cancer. 2023;186:172-184.
    PubMed     Abstract available
    
    
    
26. PERRONE E, Capasso I, De Felice F, Giannarelli D, et al
    Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification.
    Eur J Cancer. 2023;186:98-112.
    PubMed     Abstract available
    
    
    February 2023
27. WENZEL HHB, Hardie AN, Moncada-Torres A, Hogdall CK, et al
    A federated approach to identify women with early-stage cervical cancer at low risk of lymph node metastases.
    Eur J Cancer. 2023;185:61-68.
    PubMed     Abstract available
    
    
    
28. WANG J, Cai L, Song Y, Sun T, et al
    Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study).
    Eur J Cancer. 2023;184:73-82.
    PubMed     Abstract available
    
    
    January 2023
29. HERZOG TJ, Vergote I, Gomella LG, Milenkova T, et al
    Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
    Eur J Cancer. 2023;179:136-146.
    PubMed     Abstract available
    
    
    December 2022
30. CUEVA JF, Palacio I, Churruca C, Herrero A, et al
    Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
    Eur J Cancer. 2022;182:3-14.
    PubMed     Abstract available
    
    
    
31. PANOUTSOPOULOU K, Magkou P, Dreyer T, Dorn J, et al
    tRNA-derived small RNA 3'U-tRF(ValCAC) promotes tumour migration and early progression in ovarian cancer.
    Eur J Cancer. 2022;180:134-145.
    PubMed     Abstract available
    
    
    
32. SABATIER R, Rousseau F, Joly F, Cropet C, et al
    Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged >/=65 years from the PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2022;181:42-52.
    PubMed     Abstract available
    
    
    September 2022
33. XU B, Hu X, Li W, Sun T, et al
    Palbociclib plus letrozole versus placebo plus letrozole in Asian postmenopausal women with oestrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Primary results from PALOMA-4.
    Eur J Cancer. 2022;175:236-245.
    PubMed     Abstract available
    
    
    
34. KREGTING LM, Olthof EMG, Breekveldt ECH, Aitken CA, et al
    Concurrent participation in breast, cervical, and colorectal cancer screening in the Netherlands.
    Eur J Cancer. 2022;175:180-186.
    PubMed     Abstract available
    
    
    
35. GONZALEZ-MARTIN A, Desauw C, Heitz F, Cropet C, et al
    Maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced high-grade ovarian cancer: Main analysis of second progression-free survival in the phase III PAOLA-1/ENGOT-ov25 trial.
    Eur J Cancer. 2022;174:221-231.
    PubMed     Abstract available
    
    
    August 2022
36. GOLDRAT O, De Cooman M, Mailliez A, Delbaere A, et al
    Efficacy and safety of controlled ovarian hyperstimulation with or without letrozole for fertility preservation in breast cancer patients: A multicenter retrospective study.
    Eur J Cancer. 2022;174:134-141.
    PubMed     Abstract available
    
    
    July 2022
37. OAKNIN A, Monk BJ, Vergote I, Cristina de Melo A, et al
    EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
    Eur J Cancer. 2022 Jul 31. pii: S0959-8049(22)00160.
    PubMed     Abstract available
    
    
    
38. ANDERSON RA, Lambertini M, Hall PS, Wallace WH, et al
    Survival after breast cancer in women with a subsequent live birth: Influence of age at diagnosis and interval to subsequent pregnancy.
    Eur J Cancer. 2022;173:113-122.
    PubMed     Abstract available
    
    
    
39. PASHANKAR F, Hanley K, Lockley M, Stoneham S, et al
    Addressing the diagnostic and therapeutic dilemmas of ovarian immature teratoma: Report from a clinicopathologic consensus conference.
    Eur J Cancer. 2022;173:59-70.
    PubMed     Abstract available
    
    
    June 2022
40. PESENTI C, Beltrame L, Velle A, Fruscio R, et al
    Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis.
    Eur J Cancer. 2022;171:85-95.
    PubMed     Abstract available
    
    
    
41. ALTUNDAG K
    Re: Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study: Higher visceral tumour burden and weak estrogen rece
    Eur J Cancer. 2022;171:43.
    PubMed    
    
    
    
42. HEIMOVAARA JH, Boere IA, de Haan J, van Calsteren K, et al
    Ten-year experience of a national multidisciplinary tumour board for cancer and pregnancy in the Netherlands.
    Eur J Cancer. 2022;171:13-21.
    PubMed     Abstract available
    
    
    May 2022
43. SIMON S, Francis KE, Dalrymple JE, Gebski V, et al
    Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2022;170:169-178.
    PubMed     Abstract available
    
    
    
44. AMANT F, Nekljudova V, Maggen C, Seither F, et al
    Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.
    Eur J Cancer. 2022;170:54-63.
    PubMed     Abstract available
    
    
    
45. PAULET L, Trecourt A, Leary A, Peron J, et al
    Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
    Eur J Cancer. 2022;166:87-99.
    PubMed     Abstract available
    
    
    April 2022
46. AKESSON A, Adok C, Dahm-Kahler P
    Increased survival in non-endometrioid endometrial cancer after introducing lymphadenectomy and tailoring radiotherapy - A population-based cohort study.
    Eur J Cancer. 2022;169:54-63.
    PubMed     Abstract available
    
    
    
47. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
    Eur J Cancer. 2022;168:12-24.
    PubMed     Abstract available
    
    
    March 2022
48. CARTER TJ, George C, Harwood C, Nathan P, et al
    Melanoma in pregnancy: Diagnosis and management in early-stage and advanced disease.
    Eur J Cancer. 2022;166:240-253.
    PubMed     Abstract available
    
    
    December 2021
49. DITTO A, De Cecco L, Paolini B, Alberti P, et al
    Validation of MiROvaR, a microRNA-based predictor of early relapse in early stage epithelial ovarian cancer as a new strategy to optimise patients' prognostic assessment.
    Eur J Cancer. 2021;161:55-63.
    PubMed     Abstract available
    
    
    
50. JIANG F, Lin JK, Xiang Y, Xu ZF, et al
    The impact of pulmonary metastases on therapeutic response and prognosis in malignant gestational trophoblastic neoplasia patients: a retrospective cohort study.
    Eur J Cancer. 2021 Dec 13. pii: S0959-8049(21)01212.
    PubMed     Abstract available
    
    
    October 2021
51. CIBULA D, Dostalek L, Jarkovsky J, Mom CH, et al
    The annual recurrence risk model for tailored surveillance strategy in patients with cervical cancer.
    Eur J Cancer. 2021;158:111-122.
    PubMed     Abstract available
    
    
    September 2021
52. VERGOTE I, Ray-Coquard I, Anderson DM, Cantuaria G, et al
    Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer.
    Eur J Cancer. 2021;157:415-423.
    PubMed     Abstract available
    
    
    
53. KANTIDAKIS G, Litiere S, Neven A, Vinches M, et al
    Efficacy thresholds for clinical trials with advanced or metastatic leiomyosarcoma patients: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group meta-analysis based on a literature review for soft-tissue sar
    Eur J Cancer. 2021;154:253-268.
    PubMed     Abstract available
    
    
    
54. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
    Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
    Eur J Cancer. 2021;154:147-156.
    PubMed     Abstract available
    
    
    March 2021
55. PUJOL P, Barberis M, Beer P, Friedman E, et al
    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
    Eur J Cancer. 2021;146:30-47.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.